共 56 条
- [1] Barry B.W., Bioavailability of topical steroids, Dermatologica, 152, 1, pp. 47-65, (1976)
- [2] Bateman D.N., Clinical pharmacology of topical steroids, Pharmacology of the skin II, pp. 239-249, (1989)
- [3] Bodor N., Farag H.H., Improved delivery through biological membranes, Journal of Medicinal Chemistry, 26, pp. 313-318, (1983)
- [4] Budgaard H., Hansen J., Studies on the stability of cortico steroids. Kinetics of the rearrangement of betamethasone-17-valerate to the 21-valerato ester in aqueous solution, International Journal of Pharmaceutics, 7, pp. 197-203, (1981)
- [5] Chernosky M.E., Schmidt J.D., Atrophy, telangiectasia and purpura after topical fluorinated corticosteroid therapy, Cutis, 13, pp. 383-386, (1974)
- [6] Cheung Y.W., Liwan P.A., Irwin W.J., Resistance to enzymatic hydrolysis as a pameter in drug potency, International Journal of Pharmaceutics, 27, pp. 325-333, (1985)
- [7] Cullen, Effective topical dermatologic therapy, Dermatologic Clinics, 7, pp. 37-42, (1989)
- [8] Deakin M.J., Current dangers and problems in the topical use of steroids, Medical Journal of Australia, 1, pp. 120-121, (1976)
- [9] du Vivier A., Tachyphylaxis to topically applied steroids, Archives of Dermatology, 112, pp. 1245-1248, (1976)
- [10] Dykes P.J., Hill S., Marks R., Assessment of the atrophogenicity potential of glucocorticoids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions, Topical corticosteroid therapy, pp. 111-118, (1988)